Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
Cat . Non | Espèces | Description du produit | Structure | Pureté | Caractéristique |
---|---|---|---|---|---|
CD7-M82E8 | Mouse | Biotinylated Mouse EMMPRIN / CD147 Protein, His,Avitag™ (MALS verified) |
|
||
CD7-HF222 | Human | FITC-Labeled Human EMMPRIN / CD147 Protein, His Tag |
|
||
CD7-H82E0 | Human | Biotinylated Human EMMPRIN / CD147 Protein, Avitag™,His Tag (MALS verified) |
|
||
CD7-H5259 | Human | Human EMMPRIN / CD147 Protein, Fc Tag |
|
||
CD7-H5222 | Human | Human EMMPRIN / CD147 Protein, His Tag (MALS verified) |
|
Immobilized Biotinylated Human EMMPRIN, Avitag,His Tag (Cat. No. CD7-H82E0) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Anti-EMMPRIN Antibody, Mouse IgG1 with a linear range of 0.1-4 ng/mL (QC tested).
The purity of Biotinylated Human EMMPRIN, His,Avitag (Cat. No. CD7-M82E8) is more than 85% and the molecular weight of this protein is around 28-42 kDa verified by SEC-MALS.
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Iodine[131I] Metuximab | Approved | Chengdu Huasun Biotechnology Co Ltd | Licartin, 利卡汀 | Mainland China | Carcinoma, Hepatocellular | Chengdu Huasun Biotechnology Co Ltd | 2006-10-12 | Carcinoma, Hepatocellular | Details | |
Iodine[131I] Metuximab | Approved | Chengdu Huasun Biotechnology Co Ltd | Licartin, 利卡汀 | Mainland China | Carcinoma, Hepatocellular | Chengdu Huasun Biotechnology Co Ltd | 2006-10-12 | Carcinoma, Hepatocellular | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Mertuzumab | Phase 3 Clinical | Jiangsu Pacific-Meinuoke Bio-Pharmaceutical Co Ltd, Institute Of Medicine Fourth Military Medical University | Coronavirus Disease 2019 (COVID-19); Carcinoma, Non-Small-Cell Lung | Details | |
Meplazumab | HI6H8 | Phase 3 Clinical | Jiangsu Pacific-Meinuoke Bio-Pharmaceutical Co Ltd, Institute Of Medicine Fourth Military Medical University | Malaria; Coronavirus Disease 2019 (COVID-19); Malaria, Falciparum | Details |
Anti-CD147 CAR T cell therapy (Xijing Hospital) | Phase 1 Clinical | The First Affiliated Hospital of Air Force Medical University | Glioblastoma | Details | |
CD147-CAR T cell therapy (Peking University People's Hospital) | Phase 1 Clinical | Peking University People'S Hospital | Lymphoma, T-Cell | Details | |
89Zr-CD147 | Phase 1 Clinical | Solid tumours | Details | ||
Mertuzumab | Phase 3 Clinical | Jiangsu Pacific-Meinuoke Bio-Pharmaceutical Co Ltd, Institute Of Medicine Fourth Military Medical University | Coronavirus Disease 2019 (COVID-19); Carcinoma, Non-Small-Cell Lung | Details | |
Meplazumab | HI6H8 | Phase 3 Clinical | Jiangsu Pacific-Meinuoke Bio-Pharmaceutical Co Ltd, Institute Of Medicine Fourth Military Medical University | Malaria; Coronavirus Disease 2019 (COVID-19); Malaria, Falciparum | Details |
Anti-CD147 CAR T cell therapy (Xijing Hospital) | Phase 1 Clinical | The First Affiliated Hospital of Air Force Medical University | Glioblastoma | Details | |
CD147-CAR T cell therapy (Peking University People's Hospital) | Phase 1 Clinical | Peking University People'S Hospital | Lymphoma, T-Cell | Details | |
89Zr-CD147 | Phase 1 Clinical | Solid tumours | Details |
This web search service is supported by Google Inc.